Literature DB >> 1420329

A growth-dependent post-translational modification of annexin VI.

S E Moss1, S M Jacob, A A Davies, M J Crumpton.   

Abstract

Annexin VI (p68, 67-kDa calelectrin) is a member of a family of Ca2+/phospholipid-binding proteins, that includes p35 (annexin I) and p36 (annexin II), the major cellular substrates for phosphorylation by the epidermal growth factor receptor and pp60v-src tyrosine kinase activities, respectively. We report here that like annexins I and II, annexin VI is phosphorylated in vivo, but that in contrast, annexin VI phosphorylation is associated with cell growth. In both Swiss 3T3 fibroblasts and human T-lymphoblasts the pattern of phosphorylation followed an almost identical profile. In particular, annexin VI was not phosphorylated in quiescent cells, but was phosphorylated on serine and to a lesser extent threonine, several hours following cell stimulation. Furthermore, annexin VI also incorporated phosphate in a growth-dependent manner, in a form other than a phosphoamino-acid. The phosphate was visualised following acid hydrolysis of immunoprecipitated annexin VI, as part of a complex having high mobility on 2-D thin-layer electrophoresis. The identity of this complex is not known. The results suggest that a post-translational modification other than direct protein phosphorylation may influence the activity of annexin VI and provide evidence linking cell growth with regulation of annexin VI function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1420329     DOI: 10.1016/0167-4838(92)90045-f

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Functional implications of structural predictions for alternative splice proteins expressed in Her2/neu-induced breast cancers.

Authors:  Rajasree Menon; Ambrish Roy; Srayanta Mukherjee; Saveliy Belkin; Yang Zhang; Gilbert S Omenn
Journal:  J Proteome Res       Date:  2011-10-28       Impact factor: 4.466

2.  Annotation of Alternatively Spliced Proteins and Transcripts with Protein-Folding Algorithms and Isoform-Level Functional Networks.

Authors:  Hongdong Li; Yang Zhang; Yuanfang Guan; Rajasree Menon; Gilbert S Omenn
Journal:  Methods Mol Biol       Date:  2017

Review 3.  Functional and genetic analysis of annexin VI.

Authors:  H C Edwards; S E Moss
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

4.  Differential expression and localization of annexin V in cardiac myocytes during growth and hypertrophy.

Authors:  S W Jans; Y F de Jong; C P Reutelingsperger; G J van der Vusse; M van Bilsen
Journal:  Mol Cell Biochem       Date:  1998-01       Impact factor: 3.396

Review 5.  Innovations in proteomic profiling of cancers: alternative splice variants as a new class of cancer biomarker candidates and bridging of proteomics with structural biology.

Authors:  Gilbert S Omenn; Rajasree Menon; Yang Zhang
Journal:  J Proteomics       Date:  2013-04-17       Impact factor: 4.044

6.  Identification and partial sequence analysis of novel annexins in Lytechinus pictus oocytes.

Authors:  W J Shen; J Avery; N F Totty; J J Hsuan; M Whitaker; S E Moss
Journal:  Biochem J       Date:  1994-12-15       Impact factor: 3.857

7.  Inhibition of somatosensory mechanotransduction by annexin A6.

Authors:  Ramin Raouf; Stéphane Lolignier; Jane E Sexton; Queensta Millet; Sonia Santana-Varela; Anna Biller; Alice M Fuller; Vanessa Pereira; Jyoti S Choudhary; Mark O Collins; Stephen E Moss; Richard Lewis; Julie Tordo; Els Henckaerts; Michael Linden; John N Wood
Journal:  Sci Signal       Date:  2018-06-19       Impact factor: 8.192

8.  Endocytosis occurs independently of annexin VI in human A431 cells.

Authors:  E Smythe; P D Smith; S M Jacob; J Theobald; S E Moss
Journal:  J Cell Biol       Date:  1994-02       Impact factor: 10.539

9.  Annexin VI has tumour-suppressor activity in human A431 squamous epithelial carcinoma cells.

Authors:  J Theobald; A Hanby; K Patel; S E Moss
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.